ARCHIVES

Sorafenib Targets AML Driven By Mutant FLT3 Gene

This article is from The Cancer Letter archive.

Vol. 31 No. 2 | February 29, 2008

Download PDF Visit The Full Archive

Related Articles

States Spent Only 3.2% Of Settlement Money On Smoking Cessation.

November 21, 2008

Moses, Earp to lead AACI. Funding opportunities.

September 12, 2003

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

November 25, 2011

New Jersey Insurers To Cover Patient Care Costs In Trials.

January 14, 2000

On Capitol Hill: Cancer Organizations Push Congress For Payment Of Patient Care Costs In Trials

September 17, 1999

NCI Director and Acting FDA Commissioner Andrew von Eschenbach Endorses Rep. E. Clay Shaw In Tour of Florida Congressman’s District. Von Eschenbach Praises Shaw’s “Leadership” In Seeking Funding For Research, Support of 2015 Goal.

February 3, 2006